Endocrinology, Diabetes & Metabolism Hong Kong (EDMHK) 7th Annual Meeting

26 October 2024 - 27 October 2024

Expanding role of SSAs in neuroendocrine tumour management

19 Nov 2024 by

High-dose somatostatin analogues (SSAs) can be effective and well-tolerated second-line therapies in neuroendocrine tumours (NETs) progressing on standard-dose SSAs in selected cases, according to Dr Ingrid Mak of the University of Hong Kong, at the 7th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2024).

Expanding role of SSAs in neuroendocrine tumour management

19 Nov 2024

More than 90 percent of HK’s population has CKM syndrome

05 Nov 2024 by

The proportion of Hong Kong’s population with cardiovascular-kidney-metabolic (CKM) syndrome has increased from 87.8 percent 20 years ago to 90.8 percent in 2024, an ongoing population-based, cross-sectional study of cardiovascular (CV) risk factors and disease prevalence in Hong Kong Chinese (N-CRISPS) has found.

More than 90 percent of HK’s population has CKM syndrome

05 Nov 2024